10 Sep 2015 07:00
For immediate release | 10 September 2015 |
Futura Medical plc
("Futura" or the "Company")
Grant of Options
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that on 9 September 2015 it granted options over a total of 400,000 ordinary shares of 0.2p each in the Company to Directors as detailed below.
Director | Numberof optionsgranted | Exerciseprice | Exerciseperiod | Total numberof optionsheld followingnotification | Total numberof ordinaryshares held |
J H Barder | 250,000 | 30.0p | 1 Oct 2017 - 30 Sep 2022 | 1,500,000 | 1,008,830 |
D A Martin | 150,000 | 30.0p | 1 Oct 2017 - 30 Sep 2022 | 869,279 | 280,000 |
The new options were granted under the Futura Medical plc Unapproved Share Option Scheme.
The main vesting condition of the options is that the Directors remain employed with the Company as at the date of exercise.
For further information please contact:
Futura Medical plc | |
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
Email to: james.barder@futuramedical.com | www.futuramedical.com |
N+1 Singer (Nominated Adviser and Broker) | |
Aubrey Powell / Liz Yong / Tom Smale - Corporate Finance
| Tel:+44 (0) 20 7496 3000 |
For media enquiries please contact: | |
Buchanan | |
Mark Court / Sophie Cowles / Stephanie Watson | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)